Mineralocorticoid Receptor Antagonist Use in Hospitalized Patients with Heart Failure, Reduced Ejection Fraction, and Diabetes Mellitus (from the EVEREST Trial)

Despite the well-established benefits of mineralocorticoid receptor agonists (MRAs) in heart failure with reduced ejection fraction, safety concerns remain in patients with concomitant diabetes mellitus (DM) because of common renal and electrolyte abnormalities in this population. We analyzed all-ca...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Vaduganathan, Muthiah, Cas, Alessandra Dei, Mentz, Robert J., Greene, Stephen J., Khan, Sadiya, Subacius, Haris P., Chioncel, Ovidiu, Maggioni, Aldo P., Konstam, Marvin A., Senni, Michele, Fonarow, Gregg C., Butler, Javed, Gheorghiade, Mihai
Format: Artigo
Idioma:Inglês
Publicat: 2014
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4160659/
https://ncbi.nlm.nih.gov/pubmed/25060414
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.amjcard.2014.05.064
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars